Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

ABSTRACT:

Introduction

Alemtuzumab is a highly effective pulsed immune reconstitution therapy for multiple sclerosis (MS).

Aim

To evaluate serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) in patients with relapsing-remitting MS who have been treated with Alemtuzumab over the course of 2 years.

Methods

This prospective study involved MS patients treated with Alemtuzumab at a referral MS center. Both sNfL and sGFAP were analyzed at baseline and then again at 6, 12, and 24 months post-treatment using the single molecule array (SiMoA) technique. We also recruited matched healthy controls (HCs) for comparison.

Results

The study included 46 patients (with a median age of 34.2 [Interquartile range (IQR), 28.7-42.3] years, 27 of which were

SUBMITTER: Sainz-Amo R 

PROVIDER: S-EPMC11366608 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature